January 23, 2020
Alkem Laboratories shouldn't be allowed to sell a generic version of Assertio Therapeutics' opioid painkiller Nucynta ER three years earlier than an injunction allows after changing its drug's label to dodge a patent, Assertio has told a New Jersey federal court.
April 12, 2017
A New Jersey federal judge on Tuesday entered a final judgment and injunction barring Actavis Inc., Roxane Laboratories Inc. and Alkem Laboratories Ltd. from releasing generic versions of Depomed Inc.'s opioid painkiller Nucynta until related patents expire.
September 30, 2016
Depomed Inc. won a major ruling Friday when a New Jersey federal judge said patents relating to its painkiller drug Nucynta are valid and that several generic drugmakers have infringed claims on the patents, giving the pharmaceutical giant a market lock on Nucynta products through 2025.
May 19, 2016
Actavis and two other drugmakers can't launch a generic version of Depomed Inc.'s painkiller Nucynta until the New Jersey federal judge who oversaw a patent infringement trial between the companies makes a final ruling, an order meant to maintain the status quo after the statutory 30-month stay on generic approval ends Friday.
July 26, 2013
German pharmaceuticals giant Grunenthal GmbH accused rivals Actavis Inc. and Alkem Laboratories Ltd. of infringing patents for its painkiller Nucynta by seeking federal approval for generic copies of the drug, according to a suit filed in New Jersey federal court Thursday.